Phlow Corp.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2025 | $31 M | No. 3 | $10 to $50 million | equity | SEC | |
| Aug 2022 | $24 M | No. 2 | $10 to $50 million | equity | SEC | |
| Nov 2020 | $15 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Phlow Corp. chose not to state its revenue in its newest notice of a funding round (Feb 2025).
SEC Form D · Feb 2025
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Feb 2025
That is all the official record says: Phlow Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Phlow Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 11 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Daniel Maria Hackman | Executive officer | Feb 2025 |
| David Maria Ryan | Executive officer | Feb 2025 |
| Elizabeth Maria Whalley | Executive officer | Feb 2025 |
| Eric Edwards | Executive officer | Feb 2025 |
| Robert Maria Demeria | Executive officer | Feb 2025 |
| Daniel Hackman | Executive officer | Sep 2022 |
| David Levin | Executive officer | Sep 2022 |
| Elizabeth Whalley Buono | Executive officer | Sep 2022 |
| Glenn Gerecke | Executive officer | Sep 2022 |
| Robert Demeria | Executive officer | Sep 2022 |
| Ron Barden | Executive officer | Sep 2022 |
| Andrew Robert Stiles | Executive officer | Nov 2020 |
| Daniel Robert Hackman | Executive officer | Nov 2020 |
| David Robert Levin | Executive officer | Nov 2020 |
| James Robert Mooney | Executive officer | Nov 2020 |
| Robert Robert Demeria | Executive officer | Nov 2020 |
| Anna Maria Nekoranec | Director | Feb 2025 |
| Bernard Gupton | Director | Feb 2025 |
| Eric Edwards | Director | Feb 2025 |
| Guido Villax | Director | Feb 2025 |
| Kerry Ingalls | Director | Feb 2025 |
| Marshall Summar | Director | Feb 2025 |
| Melinda Hancock | Director | Feb 2025 |
| Rosemary Gibson | Director | Feb 2025 |
| Thomas O'Malley | Director | Feb 2025 |
| Bernard F. Gupton | Director | Sep 2022 |
| Martin F. Van Trieste | Director | Sep 2022 |
| Rosemary F. Gibson | Director | Sep 2022 |
| Thomas D. O'Malley | Director | Sep 2022 |
| Marshall F. Summar | Director | Nov 2020 |